查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1678693

全球血液生物标记市场：市场规模、份额、趋势分析（按类型、应用、技术、最终用途和地区）、细分市场预测（2025-2030 年）

Blood Based Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers), By Application (Cancer), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

血液生物标记市场的成长与趋势：

根据 Grand View Research 的新报告，全球血液生物标记市场预计到 2030 年将达到 115.8 亿美元。

预计 2025 年至 2030 年期间，市场复合年增长率为 7.2%。慢性病盛行率的上升以及资金筹措将推动血液生物标记产业的发展。随着对非侵入性诊断工具的需求不断增加，政府、私人公司和研究机构正在优先资助针对多种疾病（包括癌症、心血管和神经系统疾病）的血液生物标记的开发和检验的研究。扩大投资将促进创新突破，提高生物标记的准确性和可靠性，并加速新诊断测试的商业化。此外，学术机构、生物技术公司和医疗保健提供者之间日益增多的合作将促进新技术的市场开发，进一步促进市场扩张和改善患者治疗效果。

随着高通量筛检、次世代定序(NGS) 和质谱技术的创新提高了生物标记检测的灵敏度和准确性，技术进步和产品发布正在极大地推动市场的发展。这些进步使得人们能够识别以前无法检测到的生物标记物，扩大了可透过血液检查诊断的疾病范围。此外，微流体设备和穿戴式感测器的发展使得测试速度更快、更具成本效益且侵入性更小。随着技术的不断进步，基于血液的生物标记检测的可扩展性和临床适用性不断提高，使其更易于获取，对于早期疾病检测、个人化医疗和监测治疗效果更有价值，从而推动市场成长。

Exact Sciences Corp. 公布了基于血液的结肠癌筛检测试的令人鼓舞的性能资料，凸显了基于血液的生物标记领域的一项重大进步：早期检测测试的有效性日益提高。该检测对大肠直肠癌的敏感性为 88.3%，对晚期癌前病变的敏感性为 31.2%，特异性高达 90.1%，该检测的成功证明了血液诊断在癌症筛检方面的潜力日益增长。随着越来越多创新的血液检测表现出高准确性和可靠性，对这些非侵入性早期检测解决方案的需求预计将激增，从而推动市场进一步发展。这些发展将刺激投资，改善患者的治疗效果，并加强以血液为基础的生物标记在多种癌症类型的应用。

血液生物标记市场：分析概述

  • 2024 年，基因生物标记部分成为血液生物标记产业中最大的收益部分。这是因为全面基因组分析的进步导致遗传生物标记在血液诊断中的应用越来越广泛。
  • 由于持续研究开发用于早期诊断的血液生物标记物，以及行业领导者之间的广泛合作，癌症成为 2024 年最主要的领域。癌症患者数量的增加以及对非侵入性诊断方法的需求增加正在推动这一领域的成长。
  • 由于技术进步和专注于开发创新血液生物标记的主要企业的增加，次世代定序(NGS) 领域预计将在 2024 年占据市场主导地位。
  • 2024 年，医院和诊所部门占据了最终用途部门的最大份额。这种主导地位是由于慢性病的盛行率不断上升。医院是所有先进诊断服务（如血液生物标记检测）的中心，因此患者对老牌医院更有信任，从而推动了市场成长。
  • 2024 年，北美将主导全球市场。先进诊断工具的采用率不断提高、认识不断提高、该地区行业领袖的存在以及监管部门的核准预计将促进市场成长。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 血液生物标记市场：驱动因素、趋势和范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 血液生物标记市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章 血液生物标记市场：按类型分類的估计和趋势分析

  • 全球血液生物标记市场：仪表板、按类型划分
  • 全球血液生物标记市场：变异分析（按类型）
  • 全球血液生物标记市场类型（以收益为准）
  • 基因生物标记
  • 蛋白质生物标记
  • 代谢生物标记
  • 基于细胞的生物标记
  • 表观遗传生物标记

第 5 章 血液生物标记市场：按应用分類的估计和趋势分析

  • 全球血液生物标记市场：仪表板、按应用划分
  • 全球血液生物标记市场：变异分析（按应用）
  • 全球血液生物标记市场应用情况（以收益为准）
  • 癌症
  • 心血管疾病
  • 神经系统疾病
  • 免疫系统疾病
  • 其他的

6. 血液生物标记市场：按最终用途分類的估计和趋势分析

  • 全球血液生物标记市场：仪表板、依最终用途划分
  • 全球血液生物标记市场：变异分析（依最终用途）
  • 全球血液生物标记市场按最终用途划分（以收益为准）
  • 医院和诊所
  • 诊断实验室
  • 研究和学术机构
  • 其他的

第七章血液生物标记市场：区域估计和趋势分析（按类型、应用、技术和最终用途）

  • 区域控制面板
  • 血液生物标记市场：各地区差异分析（2018-2030）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2024年）
    • Abbott
    • BIOMERIEUX
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific, Inc.
    • Bio-Rad Laboratories, Inc
    • Cleveland Diagnostics, Inc.
    • Sysmex Corporation
Product Code: GVR-4-68040-519-1

Blood Based Biomarkers Market Growth & Trends:

The global blood based biomarkers market size is expected to reach USD 11.58 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.2% from 2025 to 2030. Rise in the prevalence of chronic diseases along with expanding research and funding drives the blood based biomarkers industry. As the demand for non-invasive diagnostic tools increases, governments, private sectors, and research institutions are prioritizing the funding of studies focused on developing and validating blood-based biomarkers for a wide range of diseases, including cancer, cardiovascular disorders, and neurological conditions. This increased investment enables innovative breakthroughs, enhances the accuracy and reliability of biomarkers, and accelerates the commercialization of new diagnostic tests. Additionally, the growing collaboration between academic institutions, biotechnology companies, and healthcare providers fosters the development of novel technologies, further driving market expansion and improving patient care outcomes.

Technological advancements and launches significantly drives the market, as innovations in high-throughput screening, next-generation sequencing (NGS), and mass spectrometry enhance the sensitivity and precision of biomarker detection. These advancements enable the identification of previously undetectable biomarkers, expanding the range of diseases that can be diagnosed through blood tests. Additionally, the development of microfluidic devices and wearable sensors allows for faster, more cost-effective, and less invasive testing. As technology continues to improve, it enhances the scalability and clinical applicability of blood-based biomarker assays, making them more accessible and valuable for early disease detection, personalized medicine, and monitoring treatment efficacy, thus fueling market growth.

The announcement of Exact Sciences Corp.'s promising performance data for its blood-based colorectal cancer screening test highlights a major advancement for the blood-based biomarker sector: the increasing effectiveness of early detection tests. With sensitivity rates of 88.3% for CRC and 31.2% for advanced precancerous lesions, coupled with a high specificity of 90.1%, the success of such tests reinforces the growing potential of blood-based diagnostics in cancer screening. As more innovative blood-based tests demonstrate high accuracy and reliability, the demand for these non-invasive, early detection solutions is expected to surge, driving further advancements in the market. This progress encourages investment, enhances patient outcomes, and strengthens the adoption of blood-based biomarkers across multiple cancer types.

Blood Based Biomarkers Market Report Highlights:

  • In 2024, the genetic biomarkers segment was the largest revenue-generating sector of the blood based biomarkers industry. This is attributed to the growing adoption of genetic biomarkers in blood-based diagnostics is driven by advancements in comprehensive genomic profiling.
  • Cancer was the most dominating segment in 2024 due to the consistent research, extensive collaborations among industry leaders to develop blood-based biomarkers for early diagnosis. Increasing cases of cancer and thereby rise in the demand for non invasive methods for diagnosis fuel the segment's growth.
  • Next-Generation Sequencing (NGS) segment dominated the market in 2024 due to the advancements in the technology and rising focus of several key players to develop innovative blood-based biomarkers.
  • Hospitals and Clinics segment held the largest share of the end use segment in 2024. This dominance is attributed to the rising prevalence of chronic diseases. As hospitals are center to all the advanced diagnostic services, such as blood-based biomarker testing, patients entrust the established hospitals thus, fueling market growth.
  • The North American region is set to reign the global market in the year 2024. The rising implementation of advanced diagnostic tools, increasing wareness, presence of industry leaders in the region and regulatory approvals are anticipated to contribute to the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type, application, technology, and end-use outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Blood Based Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic diseases
      • 3.2.1.2. Advancements in biomarker technology
      • 3.2.1.3. Expanding research and funding support
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High development and validation costs
      • 3.2.2.2. Lack of reimbursement policies for biomarker treatment
  • 3.3. Blood Based Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Environmental landscape

Chapter 4. Blood Based Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Global Blood Based Biomarkers Market: Type Dashboard
  • 4.2. Global Blood Based Biomarkers Market: Type Movement Analysis
  • 4.3. Global Blood Based Biomarkers Market by Type, Revenue
  • 4.4. Genetic Biomarkers
    • 4.4.1. Genetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Protein Biomarkers
    • 4.5.1. Protein Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.6. Metabolic Biomarkers
    • 4.6.1. Metabolic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7. Cell-Based Biomarkers
    • 4.7.1. Cell-Based Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.8. Epigenetic Biomarkers
    • 4.8.1. Epigenetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Blood Based Biomarkers Market: Application Estimates & Trend Analysis

  • 5.1. Global Blood Based Biomarkers Market: Application Dashboard
  • 5.2. Global Blood Based Biomarkers Market: Application Movement Analysis
  • 5.3. Global Blood Based Biomarkers Market by Application , Revenue
  • 5.4. Cancer
    • 5.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Cardiovascular Diseases
    • 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Neurological Diseases
    • 5.6.1. Neurological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Immunological Diseases
    • 5.7.1. Immunological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Blood Based Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Global Blood Based Biomarkers Market: End Use Dashboard
  • 6.2. Global Blood Based Biomarkers Market: End Use Movement Analysis
  • 6.3. Global Blood Based Biomarkers Market by End Use, Revenue
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Research & Academic Institutes
    • 6.6.1. 6.6. Research & academic institutes market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Blood Based Biomarkers Market: Regional Estimates & Trend Analysis by Type, Application, Technology, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Abbott
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. BIOMERIEUX
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. F. Hoffmann-La Roche Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Siemens Healthineers AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Thermo Fisher Scientific, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bio-Rad Laboratories, Inc
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Cleveland Diagnostics, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Sysmex Corporation
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 4 Global Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 5 Global Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 6 Global Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 7 Global Blood Based Biomarkers, by Region, 2018 - 2030 (USD Billion)
  • Table 8 North America Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 9 North America Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 10 North America Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 11 North America Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 12 North America Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 13 U.S. Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 14 U.S. Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 15 U.S. Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 16 U.S. Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 17 Canada Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 18 Canada Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 19 Canada Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 20 Canada Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 21 Mexico Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 22 Mexico Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 23 Mexico Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 24 Mexico Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 25 Europe Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 26 Europe Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 27 Europe Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 28 Europe Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 29 Europe Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 30 Germany Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 31 Germany Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 32 Germany Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 33 Germany Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 34 UK Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 35 UK Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 36 UK Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 37 UK Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 38 France Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 39 France Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 40 France Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 41 France Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 42 Italy Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 43 Italy Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 44 Italy Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 45 Italy Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 46 Spain Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 47 Spain Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 48 Spain Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 49 Spain Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 50 Denmark Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 51 Denmark Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 52 Denmark Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 53 Denmark Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 54 Sweden Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 55 Sweden Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 56 Sweden Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 57 Sweden Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 58 Norway Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 59 Norway Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 60 Norway Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 61 Norway Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 62 Asia Pacific Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 63 Asia Pacific Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 64 Asia Pacific Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 65 Asia Pacific Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 66 Asia Pacific Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 67 China Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 68 China Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 69 China Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 70 China Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 71 Japan Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 72 Japan Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 73 Japan Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 74 Japan Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 75 India Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 76 India Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 77 India Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 78 India Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 79 South Korea Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 80 South Korea Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 81 South Korea Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 82 South Korea Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 83 Australia Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 84 Australia Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 85 Australia Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 86 Australia Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 87 Thailand Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 88 Thailand Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 89 Thailand Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 90 Thailand Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 91 Latin America Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 92 Latin America Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 93 Latin America Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 94 Latin America Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 95 Latin America Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 96 Brazil Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 97 Brazil Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 98 Brazil Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 99 Brazil Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 100 Argentina Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 101 Argentina Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 102 Argentina Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 103 Argentina Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 104 Middle East & Africa Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
  • Table 105 Middle East & Africa Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 106 Middle East & Africa Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 107 Middle East & Africa Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 108 Middle East & Africa Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 109 South Africa Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 110 South Africa Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 111 South Africa Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 112 South Africa Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 116 Saudi Arabia Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 117 UAE Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 118 UAE Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 119 UAE Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 120 UAE Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
  • Table 121 Kuwait Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
  • Table 124 Kuwait Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Blood Based Biomarkers Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Blood Based Biomarkers Market: Type Movement Analysis
  • Fig. 16 Global Blood Based Biomarkers Market, for Genetic Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 17 Global Blood Based Biomarkers Market, for Protein Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 18 Global Blood Based Biomarkers Market, for Metabolic Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 19 Global Blood Based Biomarkers Market, for Cell-Based Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 20 Global Blood Based Biomarkers Market, for Epigenetic Biomarkers, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Blood Based Biomarkers Market, for Application, 2018 - 2030 (USD Billion)
  • Fig. 22 Global Blood Based Biomarkers Market, for Cancer, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Blood Based Biomarkers Market, for Cardiovascular Diseases, 2018 - 2030 (USD Billion)
  • Fig. 24 Global Blood Based Biomarkers Market, for Neurological Diseases, 2018 - 2030 (USD Billion)
  • Fig. 25 Global Blood Based Biomarkers Market, for Immunological Diseases, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 27 Global Blood Based Biomarkers Market, for Technology, 2018 - 2030 (USD Billion)
  • Fig. 28 Global Blood Based Biomarkers Market, for Next-Generation Sequencing, 2018 - 2030 (USD Billion)
  • Fig. 29 Global Blood Based Biomarkers Market, for Polymerase Chain Reaction, 2018 - 2030 (USD Billion)
  • Fig. 30 Global Blood Based Biomarkers Market, for Immunoassays, 2018 - 2030 (USD Billion)
  • Fig. 31 Global Blood Based Biomarkers Market, for Mass Spectrometry, 2018 - 2030 (USD Billion)
  • Fig. 32 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 33 Global Blood Based Biomarkers Market: End Use Movement Analysis
  • Fig. 34 Global Blood Based Biomarkers Market, for Hospitals & Clinics, 2018 - 2030 (USD Billion)
  • Fig. 35 Global Blood Based Biomarkers Market, for Diagnostic Laboratories, 2018 - 2030 (USD Billion)
  • Fig. 36 Global Blood Based Biomarkers Market, for Research & Academic Institutes, 2018 - 2030 (USD Billion)
  • Fig. 37 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 38 Regional Marketplace: Key Takeaways
  • Fig. 39 Regional Outlook, 2024 & 2030
  • Fig. 40 Global Blood Based Biomarkers Market: Region Movement Analysis
  • Fig. 41 North America Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 42 U.S. Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 43 Canada Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 44 Mexico Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 45 Europe Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 46 Germany Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 47 UK Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 48 France Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 49 Italy Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 50 Spain Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 51 Denmark Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 52 Sweden Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 53 Norway Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 54 Asia Pacific Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 55 Japan Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 56 China Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 57 India Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Australia Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 59 South Korea Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 60 Thailand Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 61 Latin America Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 62 Brazil Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 63 Argentina Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 64 Middle East and Africa Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 65 South Africa Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 66 Saudi Arabia Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 67 UAE Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
  • Fig. 68 Kuwait Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)